

Our Oncomine assay menu is growing

Coming soon: Oncomine Comprehensive Assay Plus for comprehensive and simultaneous genomic profiling

Designed for detection of known and novel targeted and immuno-oncology biomarkers, this new solution for solid tumor testing is a broad, pan-tumor assay that spans over 500 genes and will enable simultaneous analysis of both DNA and RNA in one workflow.

This new offering will fit seamlessly into your existing Ion Chef™ and Ion GeneStudio™ system workflows, and will provide relevant variant data from integrated informatics.

- Over 500 unique genes, including driver genes across all solid tumors
- Comprehensive and simultaneous genomic profiling (from DNA and RNA) for targeted and immuno-oncology biomarkers
- All classes of variants: SNVs, indels, **CNVs**, fusions, and splice variants
- Immuno-oncology content: microsatellite instability (MSI) and tumor mutational burden (TMB)
- **Sensitive** targeted fusion **detection**
- **Low sample input** (tested with sample inputs down to 1 ng of DNA/RNA or a single slide)

- **Very low QNS**, enabling up to 99% sequencing success^{1,2}
- Fully integrated analysis and reporting
- Fast turnaround time, driven by an automated workflow that enables you to go from sample to report in days

We understand that one assay does not fit all needs. Ion Torrent™ Oncomine™ solutions offer you a spectrum of assays from a small, specialized two-gene assay for BRCA to a large, 500+ gene assay for multibiomarker profiling across multiple cancer types. With Oncomine solutions, you can choose the best solution for your specific oncology research needs.

References

1. Anna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner et al. (2019) Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. *Int J Cancer*. <https://doi.org/10.1002/ijc.32133>.
2. Chih-Jian Lih, Robin D. Harrington, David J. Sims et al. (2017) Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial. *J Mol Diagn* 19(2):313-327. <https://doi.org/10.1016/j.jmoldx.2016.10.007>.

The content provided herein may relate to products that have not been officially released and is subject to change without notice.

Find out more at oncomine.com/comprehensive-assay

ThermoFisher
SCIENTIFIC